| Primary |
| Hiv Infection |
71.8% |
| Product Used For Unknown Indication |
11.7% |
| Antiviral Treatment |
3.9% |
| Drug Use For Unknown Indication |
1.9% |
| Antiretroviral Therapy |
1.5% |
| Hiv Infection Cdc Category C3 |
1.5% |
| Acquired Immunodeficiency Syndrome |
1.0% |
| Asthma |
1.0% |
| Insomnia |
1.0% |
| Prostatic Adenoma |
1.0% |
| Tuberculosis |
1.0% |
| Antiviral Prophylaxis |
0.5% |
| Arthritis |
0.5% |
| Herpes Virus Infection |
0.5% |
| Hypertension |
0.5% |
| Skin Disorder |
0.5% |
| Vaginal Infection |
0.5% |
|
| Maternal Exposure During Pregnancy |
18.6% |
| Anaemia |
7.0% |
| Lipodystrophy Acquired |
7.0% |
| Myocardial Infarction |
7.0% |
| Angioedema |
4.7% |
| Hypersensitivity |
4.7% |
| Live Birth |
4.7% |
| Nausea |
4.7% |
| Ocular Icterus |
4.7% |
| Oropharyngeal Pain |
4.7% |
| Overdose |
4.7% |
| Polyneuropathy |
4.7% |
| Pyrexia |
4.7% |
| Rash |
4.7% |
| Acute Myocardial Infarction |
2.3% |
| Aphagia |
2.3% |
| Arteriosclerosis Coronary Artery |
2.3% |
| Atrioventricular Block |
2.3% |
| Blood Amylase Increased |
2.3% |
| Blood Bilirubin Increased |
2.3% |
|
| Secondary |
| Hiv Infection |
57.0% |
| Product Used For Unknown Indication |
13.2% |
| Drug Exposure During Pregnancy |
6.3% |
| Antiretroviral Therapy |
5.3% |
| Mycobacterium Avium Complex Infection |
3.7% |
| Hypertension |
2.2% |
| Hypercholesterolaemia |
1.6% |
| Pneumocystis Jiroveci Pneumonia |
1.2% |
| Prophylaxis Against Transplant Rejection |
1.2% |
| Rash |
1.2% |
| Acquired Immunodeficiency Syndrome |
1.0% |
| Antiviral Prophylaxis |
0.8% |
| Hiv Test Positive |
0.8% |
| Prophylaxis |
0.8% |
| Type 2 Diabetes Mellitus |
0.8% |
| Anaemia |
0.6% |
| Cardiovascular Disorder |
0.6% |
| Cytomegalovirus Infection |
0.6% |
| Depression |
0.6% |
| Antiallergic Therapy |
0.2% |
|
| Renal Colic |
8.6% |
| Renal Failure Acute |
8.6% |
| Blood Alkaline Phosphatase Increased |
6.9% |
| Pregnancy |
6.9% |
| Rhabdomyolysis |
6.9% |
| Acute Myocardial Infarction |
5.2% |
| Erythema |
5.2% |
| Laboratory Test Abnormal |
5.2% |
| Maternal Exposure Timing Unspecified |
5.2% |
| Pneumothorax |
5.2% |
| Vaginal Haemorrhage |
5.2% |
| Abortion Spontaneous |
3.4% |
| Angioedema |
3.4% |
| Drug Resistance |
3.4% |
| Eosinophilia |
3.4% |
| Hepatic Failure |
3.4% |
| Nephrolithiasis |
3.4% |
| Osteonecrosis |
3.4% |
| Paraesthesia |
3.4% |
| Prostate Cancer |
3.4% |
|
| Concomitant |
| Hiv Infection |
72.9% |
| Product Used For Unknown Indication |
4.0% |
| Acquired Immunodeficiency Syndrome |
3.7% |
| Prophylaxis |
3.0% |
| Cerebral Toxoplasmosis |
2.4% |
| Epilepsy |
2.4% |
| Hiv Test Positive |
1.5% |
| Diabetes Mellitus |
1.2% |
| Hypertension |
1.2% |
| Idiopathic Thrombocytopenic Purpura |
0.9% |
| Renal Transplant |
0.9% |
| Respiratory Tract Infection |
0.9% |
| Antiretroviral Therapy |
0.6% |
| B-cell Lymphoma |
0.6% |
| Breast Cancer |
0.6% |
| Chronic Myeloid Leukaemia |
0.6% |
| Drug Use For Unknown Indication |
0.6% |
| Gout |
0.6% |
| Hepatitis B |
0.6% |
| Hepatitis C |
0.6% |
|
| Rash Maculo-papular |
8.8% |
| Renal Tubular Necrosis |
8.8% |
| Cerebral Toxoplasmosis |
7.0% |
| Drug Interaction |
7.0% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
7.0% |
| Febrile Neutropenia |
5.3% |
| Phlebitis |
5.3% |
| Prostate Cancer |
5.3% |
| Psychomotor Hyperactivity |
5.3% |
| Viral Load Increased |
5.3% |
| Bradycardia |
3.5% |
| Drug Exposure During Pregnancy |
3.5% |
| Drug Ineffective |
3.5% |
| Enlarged Clitoris |
3.5% |
| Foetal Distress Syndrome |
3.5% |
| Myasthenia Gravis |
3.5% |
| Overdose |
3.5% |
| Renal Colic |
3.5% |
| Renal Tubular Acidosis |
3.5% |
| Tendon Rupture |
3.5% |
|
| Interacting |
| Hiv Infection |
50.0% |
| Aggression |
16.7% |
| Anxiety |
16.7% |
| Depression |
16.7% |
|
| Abnormal Weight Gain |
100.0% |
|
